`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`
`
`
`
`
`
`
`
`
`BEFORE THE PATENT TRIAL AND APPEALS BOARD
`
`
`
`
`
`
`
`
`
`AMERIGEN PHARMACEUTICALS LIMITED,
`
`Petitioner,
`
`v.
`
`SHIRE LLC,
`
`
`
`
`
`Patent Owner
`
`
`
`
`
`
`
`
`
`
`
`
`PETITIONER’S REQUEST FOR ORAL ARGUMENT
`
`Case No.: IPR2015-02009
`Patent No.: Re 42,096
`
`
`
`
`
`
`
`
`
`
`
`
`
`– 1 –
`
`Polaris Innovations LTD Exhibit 2010
`Kingston v. Polaris, IPR2016-01622
`Page 2010-1
`
`
`
`
`
`Pursuant to the Paper #9, Scheduling Order at 4 and 37 C.F.R. § 42.70(a),
`
`see also, 35 U.S.C. 326(a)(10), Petitioner Amerigen Pharmaceuticals Limited sub-
`
`mits this Request for Oral Argument on the following issues:
`
`1.
`
`As presented in the Paper #8, Decision, Institution of Inter Partes
`
`Review, 37 C.F.R. § 42.108 (April 18, 2016) (“Institution Decision”):
`
`a. Whether Claims 18–21 and 23 are invalid on the evidence of
`
`record on the basis of anticipation by Mehta1, from the Paper
`
`#8, Institution Decision at 25–28, 31; and
`
`b. Whether Claims 18–21, 23, and 25 are invalid on the evidence
`
`of record on the basis of obviousness over Mehta and the
`
`Adderall PDR2, from the Paper #8, Institution Decision at 34–
`
`36
`
`2.
`
`As presented
`
`in Paper #10, Patent Owner’s Request
`
`for
`
`Reconsideration, whether the Institution Decision instituted inter partes review of
`
`Claim 25 or instituted inter partes review of only some part less than the whole of
`
`Claim 25.
`
`3.
`
`As presented by Petitioner’s Paper #11, Motion Presenting Request
`
`for Rehearing Under 37 C.F.R. § 42.71(d) of Decision Denying-In-Part Institution
`
`
`1 U.S. Patent No. 5,837,284 (filed July 14, 1997) (“Mehta”) (Ex. 1003).
`2 PHYSICIANS’ DESK REFERENCE 331, 2209–11 (51st ed. 1997) (“Adderall
`PDR”) (Ex. 1004).
`
`– 2 –
`
`Polaris Innovations LTD Exhibit 2010
`Kingston v. Polaris, IPR2016-01622
`Page 2010-2
`
`
`
`
`
`of Inter Partes Review, whether the claim language “essentially all . . . within
`
`about 60 minutes” is expressly disclosed and presumptively enabled by Mehta,
`
`without regard to inherency, as shown through the unrebutted testimony of
`
`Dr. Elder (Exhibit 1005 ¶ 283), such that the Board should reconsider (i) its denial
`
`of institution as to Claims 1–3, 5, 8–9, 11, and 25 on grounds of anticipation by
`
`Mehta, (ii) its denial of institution of Claims 1–3, 5, 8–9, and 11 on grounds of
`
`obviousness over Mehta and the Adderall PDR, and (iii) its denial of institution as
`
`to Claims 8, 9, and 11 on grounds of obviousness over Mehta, the 1997 Adderall
`
`ADR, and Rosen.
`
`4.
`
`As presented by Paper #15, Patent Owner’s Motion to Amend; by
`
`Paper #17, Petitioner’s Opposition to Motion to Amend; and by Paper #21, Patent
`
`Owner’s Reply to Petitioner’s Opposition to Motion to Amend:
`
`a. Whether Patent Owner met its burden of showing that the proposed
`
`amended claim under its broadest reasonable interpretation would be
`
`valid over all art known to the Patent Owner, including, for example,
`
`but not limited to, art not cited in the Paper #1, Petition for Inter
`
`Partes Review of USPN RE42,096 under 35 U.S.C. §§ 311–319 and
`
`37 C.F.R. 42.1–42.80 and 42.100–42.123, but otherwise disclosed to
`
`the Patent Owner in related litigation;
`
`– 3 –
`
`Polaris Innovations LTD Exhibit 2010
`Kingston v. Polaris, IPR2016-01622
`Page 2010-3
`
`
`
`
`
`b. Whether the proposed amended Claim 25 under its broadest
`
`reasonable interpretation would be valid in light of the unrebutted
`
`evidence of record teaching every limitation of proposed amended
`
`Claim 25 as it depends from Claim 2, including the claim language
`
`“essentially all . . . within about 60 minutes” as expressly disclosed
`
`and presumptively enabled by Mehta, without regard to inherency, as
`
`shown through the unrebutted testimony of Dr. Elder (e.g., Exhibit
`
`1005 ¶ 283); and
`
`c. Whether the proposed amendment should be denied for Patent
`
`Owner’s failure to show good cause for its untimely filing.
`
`5.
`
`Any issues presented in motions to exclude evidence filed in
`
`accordance with Paper #9, Scheduling Order.
`
`Paper #9, Scheduling Order, at 6 has previously set oral argument (if
`
`requested) on the instituted claims for January 10, 2017. Petitioner requests that
`
`oral argument on all pending issues identified hereinabove be heard on that date, or
`
`at such other date and time as the Board may set.
`
`Dated: December 9, 2016
`
`/Marc R. Wezowski/
`
`
`
`Marc R. Wezowski, Reg. No. 73,825
`Lead Counsel for Petitioner
`marc.wezowski@huschblackwell.com
`Philip D. Segrest, Jr., Reg. No. 39,021
`Backup Counsel for Petitioner
`philip.segrest@huschblackwell.com
`
`– 4 –
`
`Polaris Innovations LTD Exhibit 2010
`Kingston v. Polaris, IPR2016-01622
`Page 2010-4
`
`
`
`
`
`HUSCH BLACKWELL LLP
`120 South Riverside Plaza, Suite 2200
`Chicago, IL 60606
`Tel. 312-655-1500
`Fax. 312-644-1501
`
`– 5 –
`
`Polaris Innovations LTD Exhibit 2010
`Kingston v. Polaris, IPR2016-01622
`Page 2010-5
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that under 37 C.F.R. § 42.6 a copy of the foregoing
`
`PETITIONER’S REQUEST FOR ORAL ARGUMENT was served upon the
`
`named individuals below on December 9, 2016 by email as provided by 37
`
`C.F.R. § 42.6(e)(l) and the agreement of the parties:
`
`
`
`
`December 9, 2016
`
`
`
`
`Joseph R. Robinson
`joseph.robinson@troutmansanders.com
`
`Robert Schaffer
`robert.schaffer@troutmansanders.com
`
`Dustin B. Weeks
`dustin.weeks@troutmansanders.com
`
`/Marc R. Wezowski/
`
`Marc R. Wezowski, Reg. No. 73,825
`Lead Counsel for Petitioner
`marc.wezowski@huschblackwell.com
`Philip D. Segrest, Reg. No. 39,021
`Backup Counsel for Petitioner
`philip.segrest@huschblackwell.com
`HUSCH BLACKWELL LLP
`120 South Riverside Plaza, Suite 2200
`Chicago, IL 60606
`Tel. 312-655-1500
`Fax. 312-644-1501
`
`– 6 –
`
`Polaris Innovations LTD Exhibit 2010
`Kingston v. Polaris, IPR2016-01622
`Page 2010-6
`
`